These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1305 related articles for article (PubMed ID: 21226578)

  • 21. Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease.
    Hancock-Cerutti W; Millar JS; Valentini S; Liu J; Billheimer JT; Rader DJ; Cuchel M
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.
    Saleheen D; Scott R; Javad S; Zhao W; Rodrigues A; Picataggi A; Lukmanova D; Mucksavage ML; Luben R; Billheimer J; Kastelein JJ; Boekholdt SM; Khaw KT; Wareham N; Rader DJ
    Lancet Diabetes Endocrinol; 2015 Jul; 3(7):507-13. PubMed ID: 26025389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes.
    Hafiane A; Jabor B; Ruel I; Ling J; Genest J
    Am J Cardiol; 2014 Jan; 113(2):249-55. PubMed ID: 24210679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits.
    Li C; Tu Y; Liu TR; Guo ZG; Xie D; Zhong JK; Fan YZ; Lai WY
    Int J Mol Med; 2015 Mar; 35(3):715-23. PubMed ID: 25604880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration.
    Monette JS; Hutchins PM; Ronsein GE; Wimberger J; Irwin AD; Tang C; Sara JD; Shao B; Vaisar T; Lerman A; Heinecke JW
    Circ Res; 2016 Jun; 119(1):83-90. PubMed ID: 27114438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages.
    Uto-Kondo H; Ayaori M; Ogura M; Nakaya K; Ito M; Suzuki A; Takiguchi S; Yakushiji E; Terao Y; Ozasa H; Hisada T; Sasaki M; Ohsuzu F; Ikewaki K
    Circ Res; 2010 Mar; 106(4):779-87. PubMed ID: 20075335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
    Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variants at the APOE /C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol.
    Low-Kam C; Rhainds D; Lo KS; Barhdadi A; Boulé M; Alem S; Pedneault-Gagnon V; Rhéaume E; Dubé MP; Busseuil D; Hegele RA; Lettre G; Tardif JC
    J Am Heart Assoc; 2018 Aug; 7(16):e009545. PubMed ID: 30369316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JCL roundtable: High-density lipoprotein function and reverse cholesterol transport.
    Cuchel M; Rohatgi A; Sacks FM; Guyton JR
    J Clin Lipidol; 2018; 12(5):1086-1094. PubMed ID: 30314802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
    Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
    Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
    Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus.
    Tan HC; Tai ES; Sviridov D; Nestel PJ; Ng C; Chan E; Teo Y; Wai DC
    J Clin Lipidol; 2011; 5(6):467-73. PubMed ID: 22108150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells.
    Lindstedt L; Kovanen PT
    Biochem Biophys Res Commun; 2000 Nov; 277(3):552-7. PubMed ID: 11061992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
    Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.
    Niesor EJ; Schwartz GG; Perez A; Stauffer A; Durrwell A; Bucklar-Suchankova G; Benghozi R; Abt M; Kallend D
    Cardiovasc Drugs Ther; 2015 Feb; 29(1):7-14. PubMed ID: 25749868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux.
    Ji Y; Jian B; Wang N; Sun Y; Moya ML; Phillips MC; Rothblat GH; Swaney JB; Tall AR
    J Biol Chem; 1997 Aug; 272(34):20982-5. PubMed ID: 9261096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
    N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.
    Maeba R; Kojima KI; Nagura M; Komori A; Nishimukai M; Okazaki T; Uchida S
    Atherosclerosis; 2018 Mar; 270():102-109. PubMed ID: 29407877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Density Lipoprotein Proteomic Composition, and not Efflux Capacity, Reflects Differential Modulation of Reverse Cholesterol Transport by Saturated and Monounsaturated Fat Diets.
    O'Reilly M; Dillon E; Guo W; Finucane O; McMorrow A; Murphy A; Lyons C; Jones D; Ryan M; Gibney M; Gibney E; Brennan L; de la Llera Moya M; Reilly MP; Roche HM; McGillicuddy FC
    Circulation; 2016 May; 133(19):1838-50. PubMed ID: 27081117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.